Risk assessment chart for predicting fatty liver in Japanese subjects

Tokai Journal of Experimental and Clinical Medicine

Volumn 37, Issue 4, 2012, Pages 94-101

  Inabe, Fumiyo ^a   Takahashi, Eiko ^a   Moriyama, Kengo ^a   Negami, Masako ^a   Otsuka, Hiroki ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fatty liver; Health examination; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; JAPANESE; MALE; METABOLIC SYNDROME X; PREDICTION; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ALANINE TRANSAMINASE; ASIAN CONTINENTAL ANCESTRY GROUP; FATTY LIVER; FEMALE; FORECASTING; HUMANS; JAPAN; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84871597767     PISSN: 03850005     EISSN: 21852243     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
2. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-636.
3. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010; 2: 180-193.
4. Takahashi E, Yamada C, Iida Y, Kubodera T, Sugimori H, Fukui T, et al. Report of the Database Creation Subcommittee: Pilot Study (in Japanese). Ningen Dock 2012; 26: 799-847.
5. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
6. Den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 644-649.
7. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
8. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003; 38: 954-961.
9. Tanaka H, Saibara T. Genetic background of NASH and environmental factor. KAN · TAN · SUI (in Japanese). 2006; 53: 301-308.
10. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalco holic fatty liver disease. Ann. Intern. Med. 2005; 143: 722-728.
11. Ishibashi E, Eguchi Y, Eguchi T, Matsunobu A, Oza N, Nakashita S, et al. Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in females. J. Gastroenterol. Hepatol. 2008; 23: 908-913.
12. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007; 22: 2118-2123.
13. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br. Med. J. (Clin. Res. Ed.)(Clin. Res. Ed.) 1986; 292: 13-15.
14. Hanley AJ, Karter AJ, Festa A, Agostino Jr R, Wagenknecht LE, Savage P, et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 2642-2647.
15. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterology 2010; 16: 2579-2588.
16. Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, et al. Identification of individuals with non-alcoholic fatty liver disease by diagnostic criteria for metabolic syndrome. World J Gastroenterology 2012; 18: 1508-1516.
17. Yamada C, Inabe F, Mitsuhashi T, Hiratsuka N, Araida N, Takahashi E. Liver Enzymes as Indicators for the Diagnosis of Metabolic Syndrome and Its Development. Ningen Dock 2010; 26: 29-36.
18. Gonzalez AS, Guerrero DB, Soto MB, Diaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the infiammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006; 60: 802-809.
19. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 2007; 119: 79-84.
20. Saito I, Yonemasu K, Inami F. Association of body mass index, body fat, and weight gain with inflammation markers among rural residents in Japan. Circ J 2003; 67: 323-329.
21. Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, et al. Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 2006; 55: 1232-1238.
22. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, et al. Relationship between adipokines, infiammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics 2006; 61: 433-440.
23. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reffects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-2715.